The Food and Drug Administration approves the labels that contain the dangers of side effects and other contraindications for prescription drugs. Nevertheless, plaintiffs have successfully brought state-law based claims premised on the theory that these labels inadequately warned of some dangers of the drug. The below panel addressed whether and/or under what circumstances such state-law claims should be pre-empted by federal law.
This Congressional Civil Justice Academy briefing featured:
Max Kennerly
Of Counsel, Tor Hoerman Law, LLC
Ana C. Reyes
Partner, Williams & Connolly
Moderator: Dennis M. Black
Acting Director of Education, Law & Economics Center
For more information, e-mail:
CCJCA@gmu.edu
CCJCA@gmu.edu